瘤学中的单克隆抗体:十年的新选择
Vaibhavi Kardile1, Atharva Kulkarni1, Brinda Nadar1
1Department of Pharmacology, AISSMS College of Pharmacy, Pune, India.
Cell biochemistry and biophysics
|July 3, 2023
概括
单克隆抗体 (mAbs) 是有效的癌症治疗方法,在过去十年中获得了许多新的批准. 本综述系统地汇编了最近批准的瘤学mAbs及其针对专业人员的作用机制.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药物开发 药物开发
背景情况:
- 单克隆抗体 (mAbs) 在治疗各种癌症,包括固体瘤和血液恶性瘤方面表现出显著的疗效.
- 一些最销的药物是mAbs,预计到2024年, pembrolizumab将成为产生最高收入的药物.
- 在过去的十年中,大量的瘤mAbs获得了监管批准,因此需要为医疗保健专业人员提供最新信息.
研究的目的:
- 提供美国FDA在过去十年内批准用于癌症治疗的单克隆抗体 (mAbs) 的系统编译.
- 详细阐述新批准的瘤学mAbs.的作用机制.
- 提供关于癌症治疗中单克隆抗体的全方位更新.
主要方法:
- 美国FDA批准的单克隆抗体 (mAbs) 的系统审查.
- 使用"FDA的药物"和PubMed数据库进行文献搜索.
- 从2010年到现在,对已批准的mAbs进行数据收集和分析.
主要成果:
- 在过去的十年中,识别和编译了许多已被批准用于瘤指示的单克隆抗体 (mAbs).
- 对最近批准的mAbs.的作用机制的详细解释.
- 概述癌症治疗中mAbs不断变化的作用和越来越多的数量.
结论:
- 单克隆抗体 (mAbs) 是现代瘤学中快速扩展和至关重要的药物类别.
- 本综述是临床医生和研究人员了解mAb疗法的最新进展的重要资源.
- 了解这些新型药物的作用机制是优化它们在癌症治疗中的临床应用的关键.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:31Hybridoma Technology
15.0K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.0K
01:27Tumor Immunotherapy
573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K